Related Experiment Video
Updated: Jun 21, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
The search for safe and effective CAR-T targets in AML.
Florian Van Oers1,2, Donovan Flumens1, Simon Haentjens1
1Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Blood Cancer Journal
|June 19, 2026
Summary
Chimeric antigen receptor (CAR)-T-cell therapy shows promise for acute myeloid leukemia (AML). This review identifies 13 novel antigens for CAR-T development, aiming to overcome challenges like chemo-resistance and improve patient survival.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Acute myeloid leukemia (AML) is an aggressive cancer with poor survival rates.
- Leukemic stem cells (LSCs) drive AML relapse and are resistant to chemotherapy.
- Chimeric antigen receptor (CAR)-T-cell therapy is effective for B-cell malignancies but faces challenges in AML.
Purpose of the Study:
- To systematically evaluate AML-associated antigens for CAR-T-cell therapy.
- To identify novel, selective targets that minimize toxicity.
- To provide a prioritized list of antigens for next-generation CAR-T development in AML.
Main Methods:
- Reviewed 63 AML-associated antigens with reported CAR constructs.
- Evaluated antigens based on expression homogeneity, LSC presence, and absence on normal stem/blood cells.
- Applied a 20-point scoring framework to prioritize targets.
Main Results:
- Identified 13 promising novel antigens for AML CAR-T therapy: ADGRE2, SIGLEC-6, IL1RAP, MUC1, CCR1, CD155, CD70, LILRB4, GRP78, CD37, ITGB2, TIM-3, and mesothelin.
- These antigens demonstrated favorable expression profiles for selective targeting.
- Discussed strategies to mitigate potential on-target/off-tumor toxicities.
Conclusions:
- Novel antigens offer improved therapeutic potential for CAR-T-cell therapy in AML.
- A prioritized antigen landscape is crucial for designing effective next-generation CARs.
- Further research and development are needed to advance CAR-T therapy for AML patients.
